Related Experiment Videos

Phenytoin elimination in newborns

Neurology
|February 1, 1983
PubMed

Insights

Phenytoin (PHT) elimination half-life (t50%) in infants varies significantly with age and concentration. PHT levels may decrease with constant doses due to these factors in newborns.

Area of Science:

  • Pharmacokinetics
  • Neonatal Medicine
  • Clinical Pharmacology

Background:

  • Phenytoin (PHT) is commonly used to treat seizures in infants.
  • Understanding PHT elimination is crucial for optimizing therapeutic drug monitoring in neonates.

Purpose of the Study:

  • To determine the apparent half-life (t50%) of phenytoin (PHT) in a cohort of infants.
  • To investigate the influence of postnatal age and initial PHT concentration (Ci) on PHT elimination.

Main Methods:

  • Measured PHT apparent half-life (t50%) 30 times in 16 infants (2-36 days old) with seizures.
  • Analyzed the relationship between t50%, postnatal age, and initial PHT concentration (Ci).

Main Results:

  • During the first week of life, PHT t50% ranged widely from 6 to 140 hours.
  • After the first week, PHT elimination became concentration-dependent, with t50% decreasing as postnatal age increased.
  • Controlling for Ci, average t50% decreased threefold from the first week (57.3 ± 48.2 hours) to the fourth week (19.7 ± 1.31 hours).

Conclusions:

  • Both age-related changes and concentration-dependent PHT elimination contribute to decreasing PHT levels in newborns receiving constant doses.
  • These findings highlight the importance of individualized dosing and therapeutic drug monitoring for phenytoin in the neonatal population.

Related Concept Videos